Systemic Mastocytosis: Diagnostic and Therapeutic Updates
Systemic mastocytosis (SM) is often called “the great imitator.” Its symptoms are frequently complex and can mimic those of several other disorders, including those of immunologic, neurologic, dermatologic and endocrine etiologies. Individuals can suffer for years before assessments correctly reveal the presence of this disease due to its relative rarity and difficult diagnosis.
This activity will review the symptoms and signs of SM, provide an overview of new and current therapies and identify SM guideline updates. The value of an interdisciplinary team–based approach along the continuum of care for affected individuals will also be discussed as a definitive step toward optimizing outcomes.
This activity is provided by Optum Health Education.
An unrestricted educational grant was received from Blueprint Medicines Corporation.
Please ensure you are using the web-browser Chrome and disable any pop-up blocking software. Click here for information on how to enable pop-ups.
This activity is designed to meet the educational needs of case managers, dietitians, nurses, nurse practitioners, pharmacists, pharmacy technicians, physicians, PAs, and other health care professionals (HCPs) who care for individuals with SM.
This activity may be of special interest to HCPs in the fields of primary care, dermatology, allergy, hematology/oncology and medical case management.
At the end of this educational activity, participants should be able to:
- Define the clinical manifestations and incidence of SM, diagnostic criteria and when to consider SM.
- Identify the genetic mutation linked with SM and the pathogenesis of disease.
- Describe how recently approved therapies and current treatments for SM can be utilized to optimize outcomes.
- Recognize the role of the multispecialty health care team in determining diagnostic testing.
- Discuss recently updated guidelines issued by the National Comprehensive Cancer Network®.
Daniel J. DeAngelo, MD, PhD
Chief of the Division of Leukemia
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
About the presenter
Dr. Daniel J. DeAngelo earned his MD and PhD in molecular genetics from Albert Einstein College of Medicine of Yeshiva University in Bronx, New York. He completed his internship and residency at Massachusetts General Hospital in Boston and clinical fellowships in Medical Oncology and Hematology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, both in Boston.
Dr. DeAngelo’s clinical research focuses on optimizing therapy for adult leukemias, myelodysplastic syndromes and myeloproliferative disorders including systemic mast cell disorders. He is co-chair of the National Cancer Institute (NCI) leukemia steering committee. He serves on the leukemia core committee for the Alliance Cooperative Group and is principal and co-investigator of several ongoing clinical protocols. He also has an interest in the treatment of young adults with leukemia, particularly acute lymphoblastic leukemia and systemic mastocytosis.
Dr. DeAngelo has authored or coauthored more than 200 original peer-reviewed manuscripts, review articles and book chapters and has presented his work nationally and internationally.
Elizabeth V. Albert, MD
Clinical Activity Manager
Optum Health Education
Sarah Chart, RN
Optum Health Education
Disclosures of relevant financial relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, Optum Health Education (OHE) requires all those in control of educational content to disclose their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are defined by the ACCME as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies and regardless of their view of the relevance of the relationship to the education. OHE ensures that the content is independent of commercial bias.
Dr. DeAngelo has disclosed that he is an advisor/consultant for: Abbvie, Amgen, Autolus, Blueprint, Forty-Seven, Glycomimetrics, Inctye, Jazz, Kite, Novartis, Pfizer, Servier and Takeda; and received grants for clinical research from: Abbvie, Blueprint, Glycomimetics and Novartis.
The remining activity faculty or planners have no financial relationships to disclose.
All relevant financial relationships have been mitigated.
Method for calculating CE credit
CE credit was calculated by the complexity of content.
In support of improving patient care, this activity has been planned and implemented by Optum Health Education. Optum Health Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Credit designation statements
This activity was planned by and for the health care team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.
The participant will be awarded up to 1.00 contact hour(s) of credit for attendance and completion of supplemental materials.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
This activity is approved for 1.00 contact hour ([0.10] CEU) in states that recognize ACPE.
Attending the full program will earn 1.00 contact hour.
Unique Activity Number(s): JA0007123-0000-22-158-H01-P/T
Optum Health Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
The Commission for Case Manager Certification has approved this program for a maximum of 1.00 clock hours for Certified Case Managers (CCM).
Completion of this RD/DTR profession-specific or IPCE activity awards CPEUs (One IPCE credit = One CPEU).
If the activity is dietetics-related but not targeted to RDs or DTRs, CPEUs may be claimed which are commensurate with participation
1.00 contact hours (One 60-minute hour = 1 CPEU).
RDs and DTRs are to select activity type 102 in their Activity Log. Performance indicator selection is at the learner's discretion.
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been preapproved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization from which they wish to obtain credit.
- 1.00 ACPE - Pharmacists
- 1.00 ACPE - Pharmacy Technicians
- 1.00 AMA - Physicians
- 1.00 ANCC - Nurses
- 1.00 Attendance - General Attendance
- 1.00 CCMC - General - Case Managers
- 1.00 CDR - Dietitians
You must be logged into your account to participate in this activity. Get started by clicking “Begin/Continue” and completing the “Pre-Activity Assessment”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save or print your certificate of participation. A complete listing of all of your activities can be found under “My Account”, “My Activities.”